Approval · Notice of Compliance 18030 · 2016
KAZANO: Notice of Compliance 18030
Issued April 6, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18030
- Date
- April 6, 2016
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph with the final analyses of the 104-week endure study, designed to assess the durability of efficiency and safety of alogliptin compared to glipizide when use in combination with metformin in adults with type 2 diabetes mellitus
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KAZANO | Not yet assigned | — |
Medicinal ingredients
- METFORMIN HYDROCHLORIDE 500 MG per TAB
- ALOGLIPTIN BENZOATE 12.5 MG per TAB
- METFORMIN HYDROCHLORIDE 850 MG per TAB
- METFORMIN HYDROCHLORIDE 1,000 MG per TAB